Company intelligence / Profile preview
RedGene
Seoul, South Koreared-gene.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
RedGene is a South Korea-based biotechnology company founded in 2022, specializing in preclinical pharmaceutical development aimed at both human and companion animal healthcare. The company has raised $490K through grants, with support from investors such as TIPS Program and Scale Up Partners. Its scientific advisory board includes professors from leading Korean medical institutions. Specific clinical results or pipeline details are not publicly disclosed.
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on RedGene.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RedGene.